Context:

Marty Makary’s year as FDA commissioner has been marked by political brinkmanship and internal turmoil, as the administration acceded to influence over regulatory decisions and sidelined traditional staff processes. He introduced a National Priority Voucher program cleared by the White House, which critics say became a bargaining chip in drug pricing. Across his tenure, he overruled career staff, intertwined policy with partisan aims, and drew fire from vaping advocates, abortion opponents, industry, and even allies in the Trump circle. The row over flavored vapes, coupled with leadership clashes and public resignations, risks undermining the FDA’s perceived independence and foreshadows a possible dismissal. The episode signals a broader debate over how politics shapes approvals and the agency’s future trajectory.

Dive Deeper:

• Shortly after confirmation, Makary launched the Commissioner’s National Priority Voucher in June, a pilot to speed approvals for drugs tied to five national health priorities. The White House cleared all voucher decisions, transforming the program into a potential tool for political influence on pricing and access.

• The same period saw the White House publicly pressuring or shaping drug pricing deals, such as weight-loss GLP-1 drugs from Eli Lilly and Novo Nordisk, which coincided with voucher awards for related products, indicating a politicized bargaining environment near the agency’s core decisions.

• Makary repeatedly overruled career staff on controversial matters, including promises to review abortion drug safety data and later delaying the review until after midterm elections, a move framed by some as politically motivated despite official denials.

• Vinay Prasad, whom Makary hired to lead the Center for Biologics Evaluation and Research, pushed policies limiting certain vaccine access and blocking a new mRNA flu vaccine review, actions critics said aligned with Kennedy’s skepticism of COVID and vaccines and were taken against staff advice.

• A focal controversy involved flavored vaping products; Makary publicly distrusted CDC data on youth vaping and reportedly overruled FDA scientists who favored authorizing flavored vapes with age-restriction features, a decision later overridden by political dynamics associated with Trump.

• Trump’s conversations with Makary, including a dress-down over vaping policy, culminated in a shift where the FDA publicly signaled that previously blocked vapes would be allowed, illustrating how political pressure can reshape regulatory outcomes under Makary’s leadership.

• Throughout, Makary’s own rhetoric—calling for less ‘medical dogma’ and critiquing political interference—contrasted with his practical reliance on political considerations, portraying a tenure that etched a precedent for greater political influence at the agency.